Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-VV111 with or without Rapamycin in R/R CD19+ B-cell Malignancies
NCT06528301Phase 1Recruiting
- Sponsor
- Umoja Biopharma
- Start
- Mar 2025
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of UB-VV111 in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Umoja Biopharma. Primary endpoint: Adverse Events at 2 years. Started Mar 2025; status: recruiting.
02
Drugs
UB-VV111
03
Conditions
diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06528301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528301.